EUVIMEDEUVIMED entdecken
Crossref

Addressing the risk of ocular complications of GLP ‐ 1RAs ; a multi‐disciplinary expert consensus

Patrice Carter iD, Rafael Simó iD, Monica Lövestam-Adrian, Ian Pearce, Stephen C Bain iD, Christiana Dinah, Sarah Jane Davies, W David Strain iD, Philip Burgess, Amy Gamble, Chloe Hembury, Marc Evans iD

Diabetes, Obesity and Metabolism · 2025-12 · 27 (12) · 7535-7543

DOI: 10.1111/dom.70160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 08.10.2025. Verfasst von Patrice Carter und 11 weiteren Autor:innen. Beteiligte Einrichtung: Evidence Review & Synthesis, Health Economics & Outcomes Research Ltd., Cardiff, UK. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

There is current apprehension among some clinicians and conflicting evidence regarding ocular complications in relation to Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs). We aimed to generate multi‐disciplinary, expert‐led consensus recommendations relating to ocular complications to facilitate optimum prescribing of GLP‐1RAs. Materials and Methods A modified Delphi was conducted following the ACcurate COnsensus Reporting Document (ACCORD) for Delphi research. A structured literature review informed an anonymous online Delphi questionnaire, followed by a virtual consensus meeting. Eligible participants included ophthalmologists, diabetologists, and obesity specialists practising in Europe.

Results

Responses from 58 participants across 17 countries were analysed. Respondents agreed that diabetic retinopathy (DR) worsening events are primarily linked to rapid blood glucose‐lowering, rather than a direct drug effect. The benefits of GLP‐1RAs were deemed to outweigh potential ocular risks and should not limit access to these medicines. Prescribers should ensure that people with diabetes are screened for diabetic retinopathy before commencing GLP‐1RAs, particularly in high‐risk populations (>10 years duration and/or poor glucose control, (haemoglobin A1c [HbA1c] >10% or 86 mmol/mol)). When prescribing GLP‐1RA to those with sight loss in one eye and/or prior history of non‐arteritic anterior ischaemic optic neuropathy (NAION), the risk of ocular complications should be discussed. The Delphi study highlighted current uncertainty in the evidence, with some topics on the relationship between GLP‐1RAs and ocular complications reaching limited consensus.

Conclusions

Further research is needed into the direct effects of GLP‐1RAs on the retina and ocular complications. New evidence should be disseminated rapidly to optimise outcomes and safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic RetinopathyGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsDiabetes Mellitus, Type 2Eye DiseasesHumansDelphi TechniqueRisk Factors

Stichwörter der Autor:innen

Delphiconsensus recommendationsdiabetic retinopathyglucagon‐like peptide‐1 receptor agonistsnon‐arteritic anterior ischemic optic neuropathy

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Evidence Review & Synthesis, Health Economics & Outcomes Research Ltd., Cardiff, UK.
  • Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, Campus Vall d'Hebron and CIBERDEM, Barcelona, Spain.
  • Department of Ophthalmology, Lund University, Lund, Sweden.
  • St Pauls Eye Unit, Liverpool University Hospitals, NHS Foundation Trust, Liverpool, UK.
  • School of Medicine, Swansea University, Swansea, UK.
  • Ophthalmology Department, London North West University Healthcare NHS Trust, Harrow, UK.

ORCID-Profile: Patrice Carter, Rafael Simó, Stephen C Bain, W David Strain, Marc Evans

Zitieren

APA

Carter, P., Simó, R., Lövestam-Adrian, M., Pearce, I., Bain, S. C., Dinah, C., Davies, S. J., Strain, W. D., Burgess, P., Gamble, A., Hembury, C., & Evans, M. (2025). Addressing the risk of ocular complications of GLP ‐ 1RAs ; a multi‐disciplinary expert consensus. Diabetes, Obesity and Metabolism, 27(12), 7535-7543. https://doi.org/10.1111/dom.70160

Vancouver

Carter P, Simó R, Lövestam-Adrian M, Pearce I, Bain SC, Dinah C, et al. Addressing the risk of ocular complications of GLP ‐ 1RAs ; a multi‐disciplinary expert consensus. Diabetes, Obesity and Metabolism. 2025;27(12):7535-7543. doi:10.1111/dom.70160

BibTeX
@article{Carter2025,
  author = {Carter, Patrice and Simó, Rafael and Lövestam-Adrian, Monica and Pearce, Ian and Bain, Stephen C and Dinah, Christiana and Davies, Sarah Jane and Strain, W David and Burgess, Philip and Gamble, Amy and Hembury, Chloe and Evans, Marc},
  title = {Addressing the risk of ocular complications of GLP ‐ 1RAs ; a multi‐disciplinary expert consensus},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {12},
  pages = {7535--7543},
  doi = {10.1111/dom.70160}
}
Kostenlos starten →